Unity Biotechnology Inc (NAS:UBX)
$ 0.999 -0.036 (-3.48%) Market Cap: 16.83 Mil Enterprise Value: 9.10 Mil PE Ratio: 0 PB Ratio: 1.19 GF Score: 32/100

Unity Biotechnology, Inc. - Special Call Transcript

Aug 17, 2020 / 12:00PM GMT
Release Date Price: $41.5 (-66.61%)
Operator

Good morning, ladies and gentlemen, and welcome to the UNITY Biotechnology UBX0101 Phase II Top Line Results Conference Call. As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference, UNITY's Chief Financial Officer, Lynne Sullivan. Lynne, you may begin.

Lynne Marie Sullivan
Unity Biotechnology, Inc. - CFO

Thank you, operator. Good morning, and thanks to everyone for joining us. With me today are Anirvan Ghosh, our Chief Executive Officer; and Dr. Jamie Dananberg, our Chief Medical Officer.

Before we get started, I'd like to remind you that during this conference call, UNITY Biotechnology will make certain statements that are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including on our business plans and objectives and on timing and success of our clinical trials. Such forward-looking statements are not guarantees of future performance, and therefore, you should not put undue reliance upon them. These statements are subject

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot